Heron Therapeutics, Inc. (HRTX) Shares Gap Down to $17.35

Heron Therapeutics, Inc. (NASDAQ:HRTX) gapped down prior to trading on Monday . The stock had previously closed at $18.15, but opened at $17.35. Heron Therapeutics shares last traded at $16.35, with a volume of 2357100 shares trading hands.

A number of research analysts have commented on HRTX shares. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research note on Sunday. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $27.00 target price on shares of Heron Therapeutics in a report on Friday, November 10th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. Mizuho reaffirmed a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Finally, Cowen and Company reissued a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research note on Monday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $28.36.

The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The firm had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. equities analysts predict that Heron Therapeutics, Inc. will post -3.41 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new position in Heron Therapeutics in the 2nd quarter valued at $78,134,000. Vanguard Group Inc. grew its holdings in shares of Heron Therapeutics by 40.2% during the 1st quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after purchasing an additional 537,563 shares during the period. State Street Corp boosted its holdings in Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after acquiring an additional 420,113 shares during the period. Perceptive Advisors LLC acquired a new stake in Heron Therapeutics in the 3rd quarter valued at about $5,329,000. Finally, Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics during the 3rd quarter worth about $2,340,000.

ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics, Inc. (HRTX) Shares Gap Down to $17.35” was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.themarketsdaily.com/2017/11/15/heron-therapeutics-inc-hrtx-shares-gap-down-to-17-35.html.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply